biologic

Actimmune

interferon gamma-1b

Loss of exclusivityFebruary 2011projected — 12-year biologic exclusivity estimate
CompanyHorizon Therapeutics Ireland DAC

Drug detail

Brand nameActimmune
Active ingredientinterferon gamma-1b
Strength100MCG(2MILLION INTERNATIONAL UNITS)/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 1999
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Actimmune patent cliff — loss of exclusivity February 2011 | CliffBio